Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-Seed
- Development stage
- Unknown
- Lead developer
- Eckert & Ziegler
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intraprostatic
01
Overview
**I-Seed** is a brand name for **IsoSeed I-125**, a radioactive seed containing iodine-125 (I-125) used for brachytherapy in the permanent treatment of localized prostate cancer. These small, implantable seeds deliver targeted low-dose radiation directly to the tumor site, minimizing exposure to surrounding healthy tissues. Produced by Eckert & Ziegler BEBIG with calibration traceable to NIST/PTB standards, they offer good visibility under X-ray, fluoroscopy, CT, MR, and ultrasound imaging. Available as sterile loose seeds or pre-loaded in Mick Magazines for precise delivery.[8]
- Brand names
- I-SeedIsoSeed I-125
02
Targets
DNA
Beyond the preview
Go deeper on I-Seed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I-Seed.